stockrow
Saturday 7 November 2026
Export LENZ’s income statement to Excel — free account
LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- Revenue
- −72.9%
- EPS
- −67.1%
- Free cash flow
- −147.2%
Quarter to September 2026, against a year earlier
3.47
0.46
+15.28%
Follow LENZ
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (72.69%) | (59.21%) | (49.71%) | (33.63%) |
+8 more TTM periods Free account |
|
| (66.72%) | (55.52%) | (46.01%) | (31.52%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(73.91%) | (58.05%) | (44.73%) | (29.18%) | |
Average Days of Receivables |
26.96 | 7.51 | 5.96 | 0.00 | |
Free Cash Flow per Share |
(4.06) | (3.65) | (2.79) | (2.43) | |
Free Cash Flow |
(127.70) | (114.42) | (87.44) | (70.00) | |
Capital Expenditures |
(0.07) | (0.51) | (0.73) | (0.83) | |
| Other line items | |||||
Cash ROIC |
(32.80%) | (26.05%) | (17.32%) | (12.14%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.53 | 0.90 | 0.85 | 0.00 | |
Inventory Turnover |
0.91 | 0.00 | 0.00 | — | |
Average Days of Payables |
771.53 | 570.41 | 644.02 | 0.00 | |
Days of Inventory on Hand |
665.67 | 353.59 | 206.13 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
151.06% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
1,293.14% | 705.78% | 595.48% | 0.00% | |
Share Based Compensation of Revenue |
134.34% | 74.22% | 68.18% | 0.00% | |
Operating CF/Net income |
0.91 | 0.90 | 0.80 | 0.84 | |
Depreciation/Fixed assets |
0.68 | 0.45 | 0.33 | 0.24 | |
Capex/Depreciation |
(0.16) | (1.13) | (2.03) | (2.88) | |
Revenue per Share |
0.39 | 0.68 | 0.67 | 0.00 | |
Operating CF per Share |
(4.06) | (3.63) | (2.77) | (2.40) | |
Capex per Share |
0.00 | (0.02) | (0.02) | (0.03) | |
Capex to Sales |
0.01 | 0.02 | 0.04 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026